Margriet Kwint

Prognostic value of volumetric changes during concurrent chemoradiation 105 5 29. van Kranen S, Mencarelli A, van Beek S, Rasch C, van Herk M, Sonke JJ. Adaptive radiotherapy with an average anatomy model: evaluation and quantification of residual deformations in head and neck cancer patients. Radiother Oncol. 2013;109(3):463-8. 30. van de Schoot RS, M.; Winter, S.D.; Depaoli, S.;Vermunt, J.K.; . The GRoLTS-Checklist: Guidelines for Reporting on Latent Trajectory Studies. Structural Equation Modeling: A Multidisciplinary Journal. 2017 24: 451–467. 31. C. Proust-Lima, V. Philips, B. Liquet. Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm. Journal of Statistical Software. 2017;78(2):1–56. 32. Mo X, Xu-Welliver M. Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(9):e182-e3. 33. Bissonnette JP, Yap ML, Clarke K, Shessel A, Higgins J, Vines D, et al. Serial 4DCT/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy. Radiother Oncol. 2017. 34. van Timmeren JE, Leijenaar RTH, van Elmpt W, Reymen B, Oberije C, Monshouwer R, et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiother Oncol. 2017;123(3):363-9. 35. Paul J, Yang C, Wu H, Tai A, Dalah E, Zheng C, et al. Early Assessment of Treatment Responses During Radiation Therapy for Lung Cancer Using Quantitative Analysis of Daily Computed Tomography. Int J Radiat Oncol Biol Phys. 2017;98(2):463-72. 36. Forrester HB, Vidair CA, Albright N, Ling CC, Dewey WC. Using computerized video time lapse for quantifying cell death of X-irradiated rat embryo cells transfected with c-myc or c-Ha-ras. Cancer Res. 1999;59(4):931-9. 37. Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry. 1985;6(6):620- 6. 38. Earnest Ft, Ryu JH, Miller GM, Luetmer PH, Forstrom LA, Burnett OL, et al. Suspected non- small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection--pilot study. Radiology. 1999;211(1):137-45. 39. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23(13):2955- 61. 40. Na, II, Lee TH, Choe DH, Cheon GJ, Kim CH, Koh JS, et al. A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer. Eur J Cancer. 2008;44(16):2411-7. 41. Sanchez de Cos J, Sojo Gonzalez MA, Montero MV, Perez Calvo MC, Vicente MJ, Valle MH. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009;63(1):140-5. 42. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi99-105.